- Poster presentation
- Published:
Breast MRI screening for high-risk family history: the Sheffield experience
Breast Cancer Research volume 12, Article number: P53 (2010)
Introduction
Around 5% of breast cancers can be attributed to gene mutations. NICE guidelines have recently advocated the use of MRI screening in high-risk young women. We have retrospectively audited our unit’s experience in this field.
Methods
All eligible women were identified from the family history database. Notes, imaging and pathology were reviewed.
Results
One hundred and thirty-three breast MRI scans were performed on 91 women with a high-risk family history between 2007 and 2010. Sixteen women were recalled for assessment (one woman was recalled twice). The total recall rate was 12.7%. Of the recalled patients, four had normal ultrasound (US) and follow-up imaging has remained unchanged. Thirteen patients had corresponding US-detected abnormalities. Twelve were biopsied, the other was a normal intramammary lymph node. Eight of the biopsies were benign (benign core biopsy rate 6%). Four biopsies were malignant (age range of women 35 to 45), giving a cancer detection rate of 3%. Three of these were solitary lesions (8 mm, 11 mm and 16 mm). One patient had multifocal malignancy, the largest single lesion being 16 mm. All were node-negative ductal carcinoma. Two patients were oestrogen receptor-positive, all were herceptin receptor-negative. Only the extensive malignant change could be seen on conventional mammography.
Conclusions
We suggest that MRI screening is beneficial in these patients, and although our recall rate lies a little above what is to be recommended by the NHSBSP (7 to 10%) we feel this can be attributed to the steep learning curve that introducing a new screening technique to a service invariably brings.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Genever, A., Surgey, E., Ford, A. et al. Breast MRI screening for high-risk family history: the Sheffield experience. Breast Cancer Res 12 (Suppl 3), P53 (2010). https://doi.org/10.1186/bcr2706
Published:
DOI: https://doi.org/10.1186/bcr2706